Thompson, P. L.
Hui, J.
Beilby, J.
Palmer, L. J.
Watts, G. F.
West, M. J.
Kirby, A.
Marschner, S.
Simes, R. J.
Sullivan, D. R.
White, H. D.
Stewart, R.
Tonkin, A. M.
Funding for this research was provided by:
National Health and Medical Research Council (1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279, 1037786; 490968;.1010279)
Bristol-Myers Squibb
Article History
Received: 3 June 2021
Accepted: 7 February 2022
First Online: 9 March 2022
Declarations
:
: The LIPID trial was approved by the ethics committee at each participating site. All patients gave written informed consent for cohort follow-up, either in the clinic or remotely. The LIPID Genetic cohort study was approved by the Human Research Ethics Committee of Sir Charles Gairdner Hospital, Perth. The Long term follow-up of patients in the LIPID cohort study was approved by University of Sydney Human Research Ethics Committee Reference No: 01-2002/2454. The Genetic Cohort study was approved by The Human Research Ethics Committee of Sir Charles Gairdner Hospital, Perth HREC No 2011-060.
: All authors and participating patients consented to publication.
: Some authors have received research grants, travel grants or honoraria from companies that might have an interest in the submitted work: Dr Thompson from Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer; Dr White from Sanofi and Regeneron Pharmaceuticals, Omthera Pharmaceuticals, American Regent, Eisai Inc, DalCor Pharma UK Inc, CSL Behring, Sanofi Australia Pty Ltd and Esperion Therapeutics Inc. He was on the Advisory Board for Genentech Inc. Dr Tonkin from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Merck, Pfizer and Sanofi-Aventis; the other authors report no conflicts.